Study guide

1.2 Fetal Surveillance & Antepartum Diagnostics

NBRC RRT-NPS Neonatal/Pediatric Specialist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neonatal and Pediatric Patient Assessment

1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage

2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring

2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics

3 Chapter 3: Airway Management & Secretion Clearance

3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning

4 Chapter 4: Pharmacology & Medical Gas Therapy

4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation

5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders

5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration

6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety

6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care

7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation

7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk

8 Chapter 8: High-Frequency Ventilation & Advanced Modes

8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure

9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response

10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness

10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains

11 Chapter 11: Congenital Heart Disease & Hemodynamic Management

11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS

12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care

12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation

1.2 Fetal Surveillance & Antepartum Diagnostics

Key Takeaways Explain This Topic AI

Maternal magnesium crosses the placenta and can contribute to neonatal hypotonia and respiratory depression; effective ventilation remains the priority when the newborn is apneic or bradycardic.

The lecithin/sphingomyelin ratio and phosphatidylglycerol are historical biochemical indicators of fetal lung maturity. Their predictive value is imperfect, especially with diabetes or specimen contamination, so they do not guarantee absence of neonatal RDS.

A reactive non-stress test at 32 weeks or later requires at least two fetal heart rate accelerations of 15 bpm or more lasting at least 15 seconds within 20 minutes; fetuses under 32 weeks use a 10 bpm by 10 second threshold.

The biophysical profile scores fetal breathing, gross body movement, tone, amniotic fluid volume, and the non-stress test at 2 or 0 points each for a maximum of 10; a score of 4 or less is abnormal and requires prompt obstetric evaluation.

Last updated: September 2026

  • 1.2 Fetal Surveillance & Antepartum Diagnostics
  • Antenatal Diagnostic Testing & Fetal Surveillance

Evaluating fetal well-being in utero guides the timing of delivery and identifies neonates requiring advanced resuscitation equipment at birth.

Non-Stress Test (NST)

The NST monitors the fetal heart rate (FHR) response to spontaneous fetal movement using external Doppler ultrasound and tocodynamometry:

Reactive NST (Reassuring / Normal): In pregnancies ≥ 32 weeks \ge 32\text{ weeks} ≥ 32 weeks , presence of ≥ 2 \ge 2 ≥ 2 fetal heart rate accelerations of at least 15 bpm 15\text{ bpm} 15 bpm above the baseline, lasting at least 15 seconds 15\text{ seconds} 15 seconds ( 15 × 15 criterion 15\times 15\text{ criterion} 15 × 15 criterion ), within a 20-minute monitoring window. In fetuses < 32 weeks <32\text{ weeks} < 32 weeks , accelerations of ≥ 10 bpm \ge 10\text{ bpm} ≥ 10 bpm lasting ≥ 10 seconds \ge 10\text{ seconds} ≥ 10 seconds ( 10 × 10 criterion 10\times 10\text{ criterion} 10 × 10 criterion ) are considered reactive.

Non-Reactive NST (Non-Reassuring / Abnormal): Absence of sufficient accelerations over a 40-minute testing period. A nonreactive NST can reflect sleep, prematurity, medication exposure, hypoxemia, or acidemia and requires further obstetric assessment; the next test and timing depend on gestational age and the clinical context.

Biophysical Profile (BPP)

The BPP combines the NST with real-time ultrasound imaging to score five distinct parameters. Each parameter is assigned either 2 points (normal/present) or 0 points (abnormal/absent) over a 30-minute observation window. The maximum achievable score is 10 points. +-------------------------------------------------------------------------+

  • | BIOPHYSICAL PROFILE (BPP) COMPONENTS |
  • +------------------------------------+------------------------------------+
  • | 1. Fetal Breathing Movements (FBM) | >= 1 episode of sustained rhythmic |
  • | | breathing >= 30 seconds duration |
  • +------------------------------------+------------------------------------+
  • | 2. Gross Fetal Body Movements | >= 3 discrete body/limb movements |
  • +------------------------------------+------------------------------------+
  • | 3. Fetal Muscle Tone | >= 1 episode of active extension |
  • | | with rapid return to flexion |
  • +------------------------------------+------------------------------------+
  • | 4. Amniotic Fluid Volume (AFV) | >= 1 vertical pocket >= 2.0 cm |
  • | | (or Amniotic Fluid Index > 5.0 cm) |
  • +------------------------------------+------------------------------------+
  • | 5. Non-Stress Test (NST) | Reactive result (>= 2 accels) |
  • +------------------------------------+------------------------------------+
  • Clinical Interpretation of BPP Scores

Score 8/10 (with normal fluid) or 10/10: Generally reassuring. Continue management appropriate to the pregnancy and the indication for testing.

Score 8/10 with Oligohydramnios: The low fluid remains important even when the other components are reassuring; it prompts closer surveillance and consideration of delivery according to gestational age and the maternal-fetal picture.

Score 6/10: Equivocal. Repeat assessment within the time specified by the obstetric team or consider delivery based on gestational age and associated findings.

Score ≤ 4 / 10 \le 4/10 ≤ 4/10 : Abnormal and requires prompt obstetric evaluation and additional testing. Delivery may be indicated early or immediately, but the score alone neither proves asphyxia nor overrides gestational age, fluid status, fetal monitoring, and maternal condition.

Amniocentesis for Fetal Lung Maturity (FLM)

When preterm delivery is contemplated, amniotic fluid obtained via transabdominal amniocentesis can be analyzed to assess biochemical pulmonary maturity:

Lecithin-to-Sphingomyelin (L/S) Ratio:

Lecithin (Dipalmitoylphosphatidylcholine): The primary surface tension-lowering phospholipid of surfactant, which rises exponentially after 34 to 35 weeks gestation.

Sphingomyelin: A membrane phospholipid that remains relatively constant throughout late gestation, serving as an internal reference standard.

Interpretation: An L/S ratio around 2 or greater has historically suggested lower RDS risk, while a low ratio increases concern for immaturity. The test is probabilistic rather than a guarantee.

Diabetes: Maternal diabetes can delay functional surfactant maturation and weaken the reassurance provided by an apparently mature ratio. Do not apply a single universal higher cutoff; integrate phosphatidylglycerol, gestational age, maternal control, and the newborn’s condition.

Phosphatidylglycerol (PG):

A minor phospholipid (comprising ∼ 10 % \sim 10\% ∼ 10% of mature surfactant) that stabilizes the alveolar phospholipid monolayer at low lung volumes.

PG appears late in gestation, typically at 35 to 36 weeks .

Interpretation: Detectable PG supports advancing lung maturity and is less affected than the L/S ratio by some common contaminants. It is not perfectly sensitive or an absolute guarantee against RDS; specimen quality and the clinical context still matter.

Lamellar Body Count (LBC):

Lamellar bodies are the intracellular storage packets of surfactant produced by type II pneumocytes. They are similar in size to platelets and can be enumerated rapidly using a standard hematology counter.

Higher lamellar-body counts generally support advancing maturity and very low counts raise concern for RDS, but cutoffs are analyzer-, specimen-, and laboratory-specific. Use the reporting laboratory's validated interpretation rather than a universal 15,000/50,000 per microliter rule.

Worked Clinical Case: Evaluating an Equivocal Antenatal Profile

A 32-year-old Gravida 2, Para 1 female at 35 weeks gestation presents with decreased fetal movements over the preceding 24 hours. Ultrasonographic observation over 30 minutes reveals:

  • Absence of sustained fetal breathing movements (continuous apnea observed): 0 points
  • Four discrete limb movements with rolling of the torso: 2 points
  • The fetus actively opens its hand and promptly clenches it back into a fist: 2 points
  • The largest measurable vertical pocket of amniotic fluid is 1.1 cm 1.1\text{ cm} 1.1 cm : 0 points

The 20-minute NST demonstrates a baseline of 140 bpm 140\text{ bpm} 140 bpm with only one acceleration of 15 bpm 15\text{ bpm} 15 bpm lasting 15 seconds 15\text{ seconds} 15 seconds : 0 points

Total BPP Score: 2 + 2 = 4 / 10 2 + 2 = 4/10 2 + 2 = 4/10 . Clinical Decision: A BPP of 4 with oligohydramnios is abnormal and requires immediate obstetric assessment. At 35 weeks, the team should prepare for possible urgent delivery while the obstetric service integrates fetal monitoring, maternal status, and the full clinical picture; the score alone does not prove asphyxia or mandate one delivery route.

  • NPS Exam Traps
  • Exam Trap 1: The "Mature" L/S Ratio in an Infant of a Diabetic Mother

An apparently mature L/S ratio is less reassuring when maternal diabetes is poorly controlled. Treat the result as one risk estimate, not permission to dismiss grunting, retractions, tachypnea, oxygen need, or a radiographic pattern of RDS.

Exam Trap 2: Magnesium Sulfate vs. Opioid Respiratory Depression

When an infant is born limp, apneic, and hyporeflexic after maternal magnesium therapy, naloxone does not reverse magnesium exposure and is not the resuscitation priority. Establish effective positive-pressure ventilation (PPV) with an appropriate neonatal device, follow the heart-rate response, and evaluate glucose, temperature, medications, infection, and other causes while the neonatal team manages any clinically important magnesium toxicity.

Exam Trap 3: Fluid Contamination in Amniocentesis

Blood, meconium, or vaginal-fluid contamination can distort biochemical lung-maturity testing. PG may be less vulnerable than the L/S ratio to some contaminants, but verify specimen quality and avoid calling any result completely reliable in isolation.